ArticleClinicoEconomics and outcomes research : CEOR2021
Costs of Biopsy and Complications in Patients with Lung Cancer.
Article in ClinicoEconomics and outcomes research : CEOR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Prediction of oncogene mutation status in non-small cell lung cancer: a systematic review and meta-analysis with a special focus on artificial intelligence-based methods.European radiology · 2026Pooled it
- AI-Assisted OCT Imaging for Core Needle Biopsy Guidance: The 1st in Humans Study.Diagnostics (Basel, Switzerland) · 2026Article
- Liquid biopsies in precision oncology for older adults with cancer.NPJ precision oncology · 2026Review
- SinglePass electrocautery device for closure of lung and mediastinal biopsy: a case series of 5 patients.Frontiers in oncology · 2026Article
- Diagnostic patterns after adoption of shape-sensing robotic-assisted bronchoscopy: a retrospective cohort study.Annals of medicine and surgery (2012) · 2025Article
- Breath-based lung cancer detection using an ML-driven low-cost sensor array.Scientific reports · 2025Article
- Cost-effectiveness of novel diagnostic tools for idiopathic pulmonary fibrosis in the United States.BMC health services research · 2025Article
- Non-Invasive Detection of Tumors by Volatile Organic Compounds in Urine.Biomedicines · 2025Review
- The Role of Bronchoscopy in the Management of Lung Nodules. Is it too Early to Retire Transthoracic Needle Aspiration?The open respiratory medicine journal · 2025Review
- Economic Value of Bronchoscopy Technologies that Improves Sensitivity for Malignancy for Peripheral Pulmonary Lesions.Annals of the American Thoracic Society · 2024Article
- Design, infectability, and transcriptomic analysis of transregionally differentiated and scalable lung organoids derived from adult bronchial cells.bioRxiv : the preprint server for biology · 2024Article
- The association between patient preoperative disposition and outcomes after diagnostic lung biopsy.Journal of thoracic disease · 2024Article
- CRANE: A Redundant, Multi-Degree-of-Freedom Computed Tomography Robot for Heightened Needle Dexterity within a Medical Imaging Bore.IEEE transactions on robotics : a publication of the IEEE Robotics and Automation Society · 2024Article
- Clinical utility of circulating tumor DNA profiling in detecting targetable fusions in non-small cell lung cancer.Frontiers in oncology · 2024Article
- Economic Evaluation of a Novel Lung Cancer Diagnostic in a Population of Patients with a Positive Low-Dose Computed Tomography Result.Journal of health economics and outcomes research · 2024Article
- Ultrasound-Guided Needle Biopsy as an Alternative to Chamberlain's Mediastinotomy and Video-Assisted Thoracoscopic Surgery (VATS) in the Diagnosis of Anterior Mediastinal Neoformations: A Retrospective Analysis.Journal of clinical medicine · 2023Article
- Cost-effectiveness of adjuvant atezolizumab for patients with stage II-IIIA PD-L1+ non-small-cell lung cancer.Immunotherapy · 2023Article
- Review
- A brain metastasis liquid biopsy: Where are we now?Neuro-oncology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
purposeTo describe the distribution of diagnostic procedures, rates of complications, and total cost of biopsies for patients with lung cancer. PATIENTS AND
methodsObservational study using data from IBM Marketscan
resultsThe database included 22,870 patients who had a total of 37,160 biopsies, of which 16,009 (43.1%) were percutaneous, 14,997 (40.4%) bronchoscopic, 4072 (11.0%) surgical and 2082 (5.6%) mediastinoscopic. Multiple biopsies were performed on 41.9% of patients. The most common complications among patients receiving only one type of biopsy were pneumothorax (1304 patients, 8.4%), bleeding (744 patients, 4.8%) and intubation (400 patients, 2.6%). However, most complications did not require interventions that would add to costs. Median total costs were highest for inpatient surgical biopsies ($29,988) and lowest for outpatient percutaneous biopsies ($1028). Repeat biopsies of the same type increased costs by 40-80%. Complications account for 13% of total costs.
conclusionCosts of biopsies to confirm lung cancer diagnosis vary substantially by type of biopsy and setting. Multiple biopsies, inpatient procedures and complications result in higher costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.